Cameron Hajialiakbar

Cooley advised Dualitas, a biotechnology company pioneering next-generation bispecific antibody therapies for immunology and inflammation, on its $65 million Series A financing, to advance a portfolio of next-generation bispecific antibodies, including lead programs DTX-103 in allergic disease and DTX-102 for autoimmune disease, and to accelerate the development of Dualitas’ proprietary DualScreen BsAb discovery engine.

Cooley advised Vivace Therapeutics, a small molecule discovery and development company developing first-in-class cancer therapies targeting the Hippo pathway, on its $35 million Series D financing.

Cooley advised Talkiatry, a top provider of high-quality, in-network psychiatric care, on its $130 million equity and debt financing round.

Cooley advised Blue Owl Capital, a top asset manager that is redefining alternatives, on its strategic investment – consisting of a nondilutive, nonrecourse royalty-backed loan of up to $140 million – in XOMA Corporation, a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health.

Cooley represented ZitSticka, a skin care brand focused on acne treatments, on its sale to Heyday, a next-generation consumer products company pioneering a digital-first approach to brand building. Partners Nick Hobson and Anne Lieberman led the Cooley team advising ZitSticka.